

Our Ref: 13/2022
JANUARY 2022

Re: Your request made under the Freedom of Information Act 2000

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] **16**
- Adalimumab [Humira] **25**
- Adalimumab Biosimilars **323**
- Apremilast [Otezla] **3**
- Baricitinib [Olumiant] **67**
- Certolizumab [Cimzia] **0**
- Etanercept [Enbrel] **32**
- Etanercept Biosimilars **214**
- Filgotinib [Jyseleca] **0**
- Golimumab [Simponi] **45**
- Guselkumab [Tremfya] **0**
- Infliximab [Remicade] **6**
- Infliximab Biosimilars **20**
- Ixekizumab [Taltz] **5**
- Risankizumab [Skyrizi] **0**
- Rituximab [MabThera] **0**
- Rituximab Biosimilars **21**
- Sarilumab [Kevzara] **7**
- Secukinumab [Cosentyx] **48**
- Tocilizumab [Ro Actemra] **0**
- Tofacitinib [Xeljanz] **0**
- Upadacitinib [Rinvoq] **0**
- Ustekinumab [Stelara] **7**